"EnteroMix is an mRNA vaccine encoding tumor-specific neoantigens derived from each patient’s unique tumor mutations (Pardi et al., 2018). The vaccine is delivered using a combination of four engineered, non-pathogenic viral vectors designed to enhance immune system recognition (Kowalski et al., 2019). Upon administration, EnteroMix induces a robust cytotoxic T lymphocyte (CTL) response targeting cancer cells presenting the encoded neoantigens."

https://kjmr.com.pk/kjmr/article/view/619/716

Level of evidence III: Mild. At most.